Vaxcyte, Inc.
PCVX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $477 | $332 | $169 | $78 |
| G&A Expenses | $93 | $61 | $40 | $25 |
| SG&A Expenses | $93 | $61 | $40 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $75 | $23 | $0 |
| Operating Expenses | $570 | $468 | $232 | $104 |
| Operating Income | -$570 | -$468 | -$232 | -$104 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $106 | $66 | $9 | $4 |
| Pre-Tax Income | -$464 | -$402 | -$223 | -$100 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$464 | -$402 | -$223 | -$100 |
| % Margin | – | – | – | – |
| EPS | -3.8 | -4.14 | -3.44 | -1.93 |
| % Growth | 8.2% | -20.3% | -78.2% | – |
| EPS Diluted | -3.8 | -4.14 | -3.44 | -1.93 |
| Weighted Avg Shares Out | 122 | 97 | 65 | 52 |
| Weighted Avg Shares Out Dil | 122 | 97 | 65 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $110 | $63 | $8 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $16 | $10 | $9 | $3 |
| EBITDA | -$448 | -$392 | -$214 | -$97 |
| % Margin | – | – | – | – |